The Effects of a Short-Term Combined Exercise Program on Liver Steatosis Indices and the Lipidemic and Glycemic Profile in NAFLD Individuals: A Pilot Study

Non-alcoholic fatty liver disease (NAFLD) is a very common liver disease associated with obesity, unhealthy diet, and lack of physical exercise. Short-term aerobic or resistance exercise has been shown to result in reduced liver fat in patients with NAFLD; however, the impact of the combination of these types of exercise has received less attention. This study investigated the effect of a short-term (7 days) concurrent exercise training program performed daily on liver steatosis indices, as well as the glycemic and lipidemic profile of overweight/obese sedentary volunteers. Twenty adult patients (age: 47.3 ± 12.3 yrs, body mass index: 32.4 ± 3.4 kg/m2) with NAFLD, detected by ultrasound and hematological indices, participated in the study. Pre- and post-exercise intervention assessment included body weight (BW), waist circumference (WC), hip/waist ratio (H/W), Homeostasis Model Assessment Insulin Resistance (HOMA-IR), blood lipids, and steatosis indices. Fatty Liver Index, Lipid Accumulation Index, WC, H/W, triglycerides, and total cholesterol were improved (p < 0.05) post-exercise, while no differences (p > 0.05) were observed in BW, HOMA-IR, HDL, LDL, Hepatic Steatosis Index, and Framingham Steatosis Index compared to pre-exercise values. It is concluded that a 7-day combined exercise program can have beneficial effects on hepatic steatosis and central adiposity indices, independently of weight loss, in patients with NAFLD.

Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

BACKGROUND

Despite a number of treatment options, patients with diffuse large B-cell lymphoma (DLBCL) whose disease has become refractory to treatment have a poor prognosis. Selinexor is a novel, oral drug that is approved to treat patients with relapsed/refractory DLBCL. In this post hoc analysis of the SADAL study, a multinational, open-label study, we evaluated subpopulations to determine if response to single agent selinexor is impacted by number of lines of prior treatment, autologous stem cell transplant (ASCT), response to first and most recent therapies, and time to progressive disease.

PATIENTS

Patients (n = 134) with DLBCL after 2-5 prior therapies were enrolled in SADAL and received 60mg selinexor twice weekly.

RESULTS

The median overall survival was 9.0 months and median progression free survival was 2.6 months. Patients who had the best overall response rate (ORR) and disease control rate were those who had prior ASCT (42.5% and 50.0%) or responded to last line of therapy (35.9% and 43.5%). Patients with primary refractory DLBCL also showed responses (ORR 21.8%). Adverse events between subgroups were similar to the overall study population, the most common being thrombocytopenia (29.1%), fatigue (7.5%), and nausea (6.0%).

CONCLUSION

Regardless of prior therapy and disease refractory status, selinexor treatment demonstrated results consistent with its novel mechanism of action and lack of cross-resistance. Thus, single agent oral selinexor can induce deep, durable, and tolerable responses in patients with DLBCL who have recurrent disease after several chemoimmunotherapy combination regimens.

A Delphi Consensus Project to Capture Greek Experts' Opinion on the Position of Triple Therapies in COPD: Why, When and to Whom

Background

In recent years, COPD treatment has become more personalized considering specific patient's characteristics.

Aim and Methods

We have performed a DELPHI consensus project to assess the level of consensus among Greek experts on the use of triple therapy in COPD as an initial and follow-up treatment. A three-round Delphi online survey was developed. The questionnaire was developed by a 6-member steering committee, included 54 statements, and divided into 3 domains: (A) triple therapy as initial treatment (divided into subdomains examining the impact of exacerbations based on lung function, bronchodilation reversibility and/or blood eosinophil count, smoking, symptoms, and comorbidities), (B) escalation to triple therapy from dual bronchodilation and (C) de-escalation from triple therapy to dual bronchodilation. The survey was funded by AstraZeneca and was hosted and analysed by an independent external company.

Results

Consensus was reached in 84.8%, 63% and 80% of statements for domains A, B and C, respectively. Experts agreed that initial treatment with triple therapy is a reasonable option for specific patients, while escalation from dual bronchodilation to triple therapy could be considered, besides frequent exacerbators, also in patients with a history of one moderate exacerbation, mainly in the presence of marked bronchodilator reversibility or high blood eosinophil count. Finally, there was a consensus that de-escalation from triple therapy to dual bronchodilation was inappropriate in patients who had experienced one moderate exacerbation in the previous year.

Conclusion

Although consensus was generated in several statements, panelists failed to reach consensus in many aspects of the use of triple therapy, identifying areas for further research.

Accurate measurement of intrinsic positive end-expiratory pressure: how to detect and correct for expiratory muscle activity

It has been shown that expiratory muscle contraction leads to an overestimation of intrinsic positive end-expiratory pressure (PEEPi). To quantify this overestimation, we compared PEEPi, measured during spontaneous breathing (SB) by the end-expiratory airway occlusion technique (PEEPi,occl) with static PEEPi (PEEPi,st). PEEPi,st was measured using end-expiratory airway occlusion during simulation of SB by the ventilator with the patient relaxed, and was considered to represent the "gold standard" for PEEPi,occl. Twelve ventilator-dependent patients were studied during SB (pressure support 5-7 cmH2O). Full mechanical ventilation was resumed when they were unable to sustain SB. Subsequently, by manipulating the variables of the ventilator, we simulated the pattern of SB and measured PEEPi,st, corresponding to PEEPi,occl. On the basis of the presence or absence of expiratory rise in gastric pressure (Pga) (rapid drop of end-expiratory Pga at the beginning of inspiration, Pga,exp,rise), and abdominal muscle electromyographic (EMG) activity, patients were subdivided into those either actively (Group 1) or passively expiring (Group 2). In Group 1 (8 patients), PEEPi,occl was higher than PEEPi,st (13.3+/-2.0 vs 6.8+/-1.1 cmH2O; p<0.01). PEEPi,occl-Pga,exp,rise (6.9+/-1.1 cmH2O) was quite similar to PEEPi,st; their mean difference was 0.03 cmH2O with limits of agreement -0.48 to +0.53 cmH2O. In Group 2, PEEPi,occl was similar to PEEPi,st. We conclude that, in actively expiring patients, an accurate estimation of the actual PEEPi,st can be obtained by subtracting Pga,exp,rise from PEEPi,occl.

Profile of endocrinological derangements affecting PSA values in patients with COPD

BACKGROUND/AIM

Chronic obstractive pulmonary disease (COPD) in men has been associated with testosterone deficiency, known as the late-onset hypogonadism. Prostate cancer becomes more prevalent when testosterone values decline in males. We sought to determine endocrinological derangements that may affect PSA values in male patients with COPD.

MATERIALS AND METHODS

A total of 69 male patients with COPD and 82 healthy volunteers were divided into subgroups according to: their age: (i) ≤60 years and (ii) >60 years; or disease severity: (i) FEV1<50% and (ii) FEV1≥50% predicted.

RESULTS

There was a significant reduction in total and free testosterone in patients with COPD. Patients with COPD aged >60 years had significantly lower free PSA compared to the control group.

CONCLUSION

Alterations of the male hormonal status in COPD are related with older age (>60 years) and poorer lung function (FEV1<50% predicted). This may have implications for the use of the PSA-based screening tests in the elderly male population with COPD.

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

Background

Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work.

Methods

We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022.

Findings

In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs).The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79-4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49-2.11; p < 0.001/OR = 1.89; 95% CI = 1.6-2.24; p < 0.001).CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36-2.41; p < 0.001/OR = 2.11; 95% CI = 1.12-3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08-0.33; p < 0.001).Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001).

Interpretation

OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS.

Funding

AbbVie, and EU/EFPIAInnovative Medicines Initiative Joint Undertaking HARMONY grant n° 116026.

Echocardiographic and ambulatory electrocardiographic findings in elite water-polo athletes

The aim of this study was to investigate the echocardiographic and electrocardiographic findings in top water-polo athletes and test the hypothesis that their hearts exhibit dilatation associated with hypertrophy secondary to the mixed type (isotonic and isometric) of exercise they are subjected to. Eighteen athletes of the Greek national water-polo team and 15 healthy sedentary men serving as controls were studied. All underwent an echocardiogram, a standard 12-lead ECG and 24-h ECG monitoring. In athletes, as compared to healthy controls, an increase was detected in the following indices: left ventricular (LV) end-diastolic diameter index (EDDI-LV) (by 10%; P = 0.02), interventricular septal thickness (IVS) (by 32%; P<0.001), thickness of the posterior wall (PW) (by 29%; P<0.001), relative wall thickness (IVS + PW/EDD-LV) (by 12%; P < 0.001) and LV mass index (by 82%; P < 0.001). Mild asymmetric thickening of the septum (IVS/PW = 1.40 and 1.37) was measured in two athletes. LV fractional shortening was normal. Standard 12-lead ECG abnormalities (LV hypertrophy or abnormal repolarization pattern) were observed in 33% of athletes. Athletes had sinus bradycardia during day and night, respiratory arrhythmia (RA) (83% vs 40% of controls; P = 0.03) and sinus pauses (SP) (39% vs 0% of controls; P = 0.02), with occassional arrhythmias and conduction abnormalities. We conclude that top water-polo athletes have dilatation combined with substantial hypertrophy and normal systolic function of the LV In addition they present bradycardia, RA and SP, with occassional arrhythmias and conduction abnormalities.

Accurate measurement of intrinsic positive end-expiratory pressure: how to detect and correct for expiratory muscle activity

It has been shown that expiratory muscle contraction leads to an overestimation of intrinsic positive end-expiratory pressure (PEEPi). To quantify this overestimation, we compared PEEPi, measured during spontaneous breathing (SB) by the end-expiratory airway occlusion technique (PEEPi,occl) with static PEEPi (PEEPi,st). PEEPi,st was measured using end-expiratory airway occlusion during simulation of SB by the ventilator with the patient relaxed, and was considered to represent the "gold standard" for PEEPi,occl. Twelve ventilator-dependent patients were studied during SB (pressure support 5-7 cmH2O). Full mechanical ventilation was resumed when they were unable to sustain SB. Subsequently, by manipulating the variables of the ventilator, we simulated the pattern of SB and measured PEEPi,st, corresponding to PEEPi,occl. On the basis of the presence or absence of expiratory rise in gastric pressure (Pga) (rapid drop of end-expiratory Pga at the beginning of inspiration, Pga,exp,rise), and abdominal muscle electromyographic (EMG) activity, patients were subdivided into those either actively (Group 1) or passively expiring (Group 2). In Group 1 (8 patients), PEEPi,occl was higher than PEEPi,st (13.3+/-2.0 vs 6.8+/-1.1 cmH2O; p<0.01). PEEPi,occl-Pga,exp,rise (6.9+/-1.1 cmH2O) was quite similar to PEEPi,st; their mean difference was 0.03 cmH2O with limits of agreement -0.48 to +0.53 cmH2O. In Group 2, PEEPi,occl was similar to PEEPi,st. We conclude that, in actively expiring patients, an accurate estimation of the actual PEEPi,st can be obtained by subtracting Pga,exp,rise from PEEPi,occl.

Mortality prevention as the centre of COPD management

COPD is a major healthcare problem and cause of mortality worldwide. COPD patients at increased mortality risk are those who are more symptomatic, have lower lung function and lower diffusing capacity of the lung for carbon monoxide, decreased exercise capacity, belong to the emphysematous phenotype and those who have concomitant bronchiectasis. Mortality risk seems to be greater in patients who experience COPD exacerbations and in those who suffer from concomitant cardiovascular and/or metabolic diseases. To predict the risk of death in COPD patients, several composite scores have been created using different parameters. In previous years, large studies (also called mega-trials) have evaluated the efficacy of different therapies on COPD mortality, but until recently only nonpharmaceutical interventions have proven to be effective. However, recent studies on fixed combinations of triple therapy (long-acting β-agonists, long-acting muscarinic antagonists and inhaled corticosteroids) have provided encouraging results, showing for the first time a reduction in mortality compared to dual therapies. The aim of the present review is to summarise available data regarding mortality risk in COPD patients and to describe pharmacological therapies that have shown effectiveness in reducing mortality.